Replicel’s Dermal Injector Is The Company’s Nearest-term Commercial Asset Expected To Be Approved Fo

[bekeero]

RepliCel’s dermal injector is the Company’s nearest-term commercial asset expected to be approved for market launch next year in Europe and all other countries accepting such CE Marks including Hong Kong. RepliCel’s partner, YOFOTO holds the license to market the injector in Hong Kong where it plans to launch the product immediately upon registering the CE mark there.”
https://www.replicel.com/news/repli...ts-for-its-regenerative-medicine-technologies

 

[MeDK]

Old news, it have already been discussed in the other replicel thread